Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Macy's Inc (M) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Macy's Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $222.91 (market cap $29.60B), while Macy's Inc trades at $23.84 (market cap $6.45B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.6× Macy's Inc's market cap, and Macy's Inc pays a 3.12% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | M | |
|---|---|---|
Market Cap | $29.60B | $6.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $26.21 |
52-Week Low | $205.48 | $12.73 |
Enterprise Value | $27.56B | $10.26B |
Dividend Yield | — | 3.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $222.54, up 2.56% today, amid a bearish technical signal with support at $218 and resistance at $223. The company reported strong revenue growth to $3.71B in 2025 and turned profitable with net income of $313.75M, though recent Q2 2026 earnings missed estimates. Analyst consensus remains bullish with a $370.07 price target, but multiple law firms are investigating potential securities fraud, creating near-term uncertainty.
The outlook is mixed: robust fundamentals and analyst support suggest long-term upside, but legal risks and recent earnings volatility pose significant headwinds. Investors face tension between strong profitability metrics and heightened sentiment risks from ongoing investigations.
Macy's (M) trades at $23.92, down 3.94% in the last session, with a bullish technical signal and recent earnings beats. The stock shows attractive valuation metrics including a P/E of 10.13 and P/S of 0.3, while maintaining positive cash flow generation. Recent institutional buying and analyst coverage indicate growing confidence in the company's turnaround strategy.
The outlook remains cautiously optimistic with a consensus price target of $24.83 offering 4% upside potential. Key risks include retail sector headwinds and competitive pressures, but strong institutional interest and improving fundamentals support the case for gradual recovery. The dividend payment scheduled for July provides additional shareholder return.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Macy's Inc
Founded in 1858 and based in New York City, Macy's operates 570 stores under the Macy's nameplate, 58 stores under the Bloomingdale's nameplate, and 160 freestanding Bluemercury specialty beauty stores (as of the end of fiscal-year 2021). Macy's also operates e-commerce sites and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances comprised 59% of Macy's 2021 sales.
Read more on M →
